Nemer Laura, Krishna Somashekar G, Shah Zarine K, Conwell Darwin L, Cruz-Monserrate Zobeida, Dillhoff Mary, Guttridge Denis C, Hinton Alice, Manilchuk Andrei, Pawlik Timothy M, Schmidt Carl R, Talbert Erin E, Bekaii-Saab Tanios, Hart Phil A
From the *Division of Gastroenterology, Hepatology, and Nutrition, †Department of Radiology, ‡Division of Surgical Oncology, §Department of Cancer Biology and Genetics, ∥Division of Biostatistics, College of Public Health, ¶Division of General Surgery, #Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH; and **Division of Medical Oncology and Hematology, Mayo Clinic, Phoenix, AZ.
Pancreas. 2017 Oct;46(9):1152-1157. doi: 10.1097/MPA.0000000000000898.
Pancreatic ductal adenocarcinoma (PDAC) is often accompanied by weight loss. We sought to characterize factors associated with weight loss and observed nutritional interventions, as well as define the effect of weight loss on survival.
Consecutive subjects diagnosed with PDAC (N = 123) were retrospectively evaluated. Univariate analysis was used to compare subjects with and without substantial (>5%) weight loss. Multivariate logistic regression was performed to identify factors associated with weight loss, and survival analyses were performed using Kaplan-Meier curves and Cox survival models.
Substantial weight loss at diagnosis was present in 71.5% of subjects and was independently associated with higher baseline body mass index, longer symptom duration, and increased tumor size. Recommendations for nutrition consultation and pancreatic enzyme replacement therapy occurred in 27.6% and 36.9% of subjects, respectively. Weight loss (>5%) was not associated with worse survival on multivariate analysis (hazard ratio, 1.32; 95% confidence interval, 0.76-2.30), unless a higher threshold (>10%) was used (hazard ratio, 1.77; 95% confidence interval, 1.09-2.87).
Despite the high prevalence of weight loss at PDAC diagnosis, there are low observed rates of nutritional interventions. Weight loss based on current criteria for cancer cachexia is not associated with poor survival in PDAC.
胰腺导管腺癌(PDAC)常伴有体重减轻。我们试图确定与体重减轻相关的因素并观察营养干预措施,同时明确体重减轻对生存的影响。
对连续诊断为PDAC的受试者(N = 123)进行回顾性评估。采用单因素分析比较有和没有显著(>5%)体重减轻的受试者。进行多因素逻辑回归以确定与体重减轻相关的因素,并使用Kaplan-Meier曲线和Cox生存模型进行生存分析。
71.5%的受试者在诊断时出现显著体重减轻,且与较高的基线体重指数、较长的症状持续时间和肿瘤大小增加独立相关。分别有27.6%和36.9%的受试者接受了营养咨询和胰酶替代治疗的建议。多因素分析中,体重减轻(>5%)与较差的生存率无关(风险比,1.32;95%置信区间,0.76 - 2.30),除非采用更高的阈值(>10%)(风险比,1.77;95%置信区间,1.09 - 2.87)。
尽管PDAC诊断时体重减轻的发生率很高,但观察到的营养干预率较低。基于目前癌症恶病质标准的体重减轻与PDAC患者的不良生存无关。